New MHRA guidance on the assessment of established medicines in order to help applicants and shorten time frames

New guidance has been published on the MHRA website concerning process changes for the assessment of established medicines that come into effect on 1 March 2024. This post is an attempt to present the guidance information in a manner that…

Read MoreNew MHRA guidance on the assessment of established medicines in order to help applicants and shorten time frames

European Commission proposes to extend transition periods for certain IVDs, gradual roll-out of Eudamed and an information obligation in case of interruption of supply

Last updated: 23 February 2024 See updated at the end of the post. On 23 January 2024, the European Commission published a proposal to extend transition periods for certain in vitro diagnostic medical devices (IVDs), gradual roll-out of Eudamed and an…

Read MoreEuropean Commission proposes to extend transition periods for certain IVDs, gradual roll-out of Eudamed and an information obligation in case of interruption of supply

HPRA Newsletter 76 – Includes information on transition to the CTR, Brexit and multilingual DCP packaging pilot

Issue 76 (February 2024) of the HPRA Medicinal Products Newsletter has been published. As usual, it is packed with information and includes (but is not restricted to) the following information: 1) Clinical trials applications – Important dates and information Applicants…

Read MoreHPRA Newsletter 76 – Includes information on transition to the CTR, Brexit and multilingual DCP packaging pilot

EMA and FDA launch pilot program for parallel scientific advice (PSA) for hybrid products and complex generic products

Last updated: 7 February 2024 See updates at the end of the post. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have established a pilot program to provide parallel scientific advice (PSA) to applicants of…

Read MoreEMA and FDA launch pilot program for parallel scientific advice (PSA) for hybrid products and complex generic products

EU Supplementary Protection Certificate (SPC) manufacturing waiver put to the test in a Munich regional court (Janssen Biotech vs Formycon)

This post concerns a recent court case in which an EU Supplementary Protection Certificate manufacturing waiver was put to the test in a Munich court. About Supplementary Protection Certificate (SPC) manufacturing waivers With the entry into force of Regulation (EU) 2019/933 on…

Read MoreEU Supplementary Protection Certificate (SPC) manufacturing waiver put to the test in a Munich regional court (Janssen Biotech vs Formycon)

Learning from Case Law: Mylan vs Gilead (case C-473/22) on potential Supplementary Protection Certificate (SPC) infringement

This post is an attempt to present some of the salient information from Case C-473/22 concerning Mylan vs Gilead on potential Supplementary Protection Certificate (SPC) infringement. The information provided below is by no means exhaustive. In order to develop a…

Read MoreLearning from Case Law: Mylan vs Gilead (case C-473/22) on potential Supplementary Protection Certificate (SPC) infringement